Nature has yielded numerous classes of chemically distinct microtubule
stabilizers. Several of these, including paclitaxel (Taxol) and docetaxel
(Taxotere), are important drugs used in the treatment of cancer. New microtubule
stabilizers and novel formulations of these agents continue to provide advances
in cancer therapy. In this review we cover recent progress from late 2008 to
August 2013 in the chemistry and biology of these diverse microtubule
stabilizers focusing on the wide range of organisms that produce these
compounds, their mechanisms of inhibiting microtubule-dependent processes,
mechanisms of drug resistance, and their interactions with tubulin including
their distinct binding sites and modes. A new potential role for microtubule
stabilizers in neurodegenerative diseases is reviewed.